
The oral drug, used with everolimus, cut the risk of disease progression or death by 62% in a Phase III trial’s ESR1-mutated group.
The FDA approved Roche’s Wilserdly with everolimus for certain adults with ESR1-mutated, ER-positive, HER2-negative advanced breast cancer. The treatment is for patients whose disease returned after adjuvant endocrine therapy or progressed on at least one endocrine-based regimen.
In the Phase III evERA study, the combination reduced the risk of disease progression or death by 62% compared with standard endocrine therapy plus everolimus. The result was in patients with ESR1 mutations who had previously received a CDK4/6 inhibitor.
Roche said the all-oral regimen targets two signaling pathways and does not require injections. The FDA is also reviewing Wilserdly as an adjuvant treatment for early-stage breast cancer, with a decision expected by November 30, 2026.
This article was produced with the help of AI technology. Based on reporting by the outlets listed above.